TSHA

Taysha Gene Therapies, Inc. (TSHA) - 2025 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2025. Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic diseases of the central nervous system (CNS). The company's lead program, TSHA-102, targets Rett syndrome. As of the reporting date, the company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Note: Revenue is derived entirely from the Astellas Transactions (licensing options and R&D activities), not product sales.

Material Changes vs. Prior Period

• Revenue Increase: Revenue increased by $1.4 million (17%) primarily due to the expiration of the Rett Option under the Astellas agreement in October 2025, which triggered the recognition of $5.5 million in revenue.
• Expense Growth: Operating expenses increased by approximately $20.5 million. R&D expenses rose $20.4 million driven by increased headcount, clinical trial activities for TSHA-102, and a $3.0 million milestone payment to Abeona Therapeutics triggered by dosing the first patient in the pivotal REVEAL Part B trial.
• Debt Refinancing: In August 2025, the company entered into a new $50.0 million term loan with Trinity Capital, refinancing the previous $40.0 million facility. The new loan includes potential tranches contingent on BLA submission and approval.
• Cash Position: Cash and cash equivalents more than doubled to $319.8 million, fueled by a $215.6 million equity offering in May 2025 and $48.4 million from at-the-market sales.

Guidance, Outlook, and Management Commentary

• Clinical Progress: The company reported positive data from the REVEAL Phase 1/2 trials, with 100% of patients in the high-dose cohort gaining or regaining developmental milestones. The pivotal REVEAL Part B trial (enrolling 15 patients) began dosing in Q4 2025, with completion expected in Q2 2026. The ASPIRE trial for younger children (ages 2-4) is also underway.
• Regulatory Alignment: Taysha has finalized FDA alignment on the REVEAL pivotal trial protocol and statistical analysis plan, including a 6-month interim analysis that could serve as the basis for a Biologics License Application (BLA).
• Liquidity Outlook: Management believes existing cash resources ($319.8 million) are sufficient to fund operations into 2028. The company expects to continue incurring significant losses as it advances clinical trials and prepares for potential commercialization.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, reliance on third-party manufacturers, and potential limitations on the use of Net Operating Loss (NOL) carryforwards due to ownership changes.

Investor Verification Checklist

• Clinical Trial Enrollment: Verify the pace of patient enrollment in the REVEAL Part B and ASPIRE trials against the Q2 2026 completion target.
• Interim Data Readout: Monitor the timing and results of the 6-month interim analysis from the REVEAL pivotal trial, which is critical for the BLA submission strategy.
• Cash Burn Rate: Track quarterly cash burn to confirm the runway extends into 2028 as projected, given the high R&D spend.
• Debt Covenants: Review compliance with the 2025 Trinity Term Loan covenants, particularly regarding milestones for Tranche B and C funding.
• Legal Proceedings: Monitor the status of the stockholder derivative lawsuit and the SEC investigation regarding the August 2023 Private Placement, though the company has moved to dismiss the derivative action.